VIMCO emulsion for injection for ewes and female goats

País: Irlanda

Língua: inglês

Origem: HPRA (Health Products Regulatory Authority)

Ingredientes ativos:

Staphylococcus aureus SP140 CP8 strain, inactivated, expressing biofilm components

Disponível em:

Laboratorios Hipra S.A.

Código ATC:

QI03AB

DCI (Denominação Comum Internacional):

Staphylococcus aureus SP140 CP8 strain, inactivated, expressing biofilm components

Dosagem:

.

Forma farmacêutica:

Emulsion for injection

Tipo de prescrição:

POM: Prescription Only Medicine as defined in relevant national legislation

Grupo terapêutico:

Goats, Sheep

Área terapêutica:

Inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia)

Indicações terapêuticas:

Immunological - Inactivated Vaccine

Status de autorização:

Authorised

Data de autorização:

2017-09-29

Características técnicas

1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
VIMCO emulsion for injection for ewes and female goats.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One dose (2 ml) contains:
ACTIVE SUBSTANCE:
Inactivated
_Staphylococcus aureus_
, SP140 CP**8 strain, expressing Biofilm components ≥ 8.98 SaCC*
*
_Staphylococcus aureus _
Cell Count in log
10
.
** CP: capsular polysaccharide
ADJUVANT:
Liquid
paraffin……………………...............................................................................
18.2 mg
EXCIPIENTS:
QUALITATIVE COMPOSITION OF EXCIPIENTS AND
OTHER CONSTITUENTS
QUANTITATIVE COMPOSITION IF THAT INFORMATION
IS ESSENTIAL FOR PROPER ADMINISTRATION OF THE
VETERINARY MEDICINAL PRODUC
t
Benzyl alcohol
21 mg
Sorbitan monooleate
Polysorbate 80
Sodium alginate
Calcium chloride, dihydrate
Simethicone
Sodium chloride
Potassium chloride
Disodium phosphate dodecahydrate
Potassium dihydrogen phosphate
Water for injections
Ivory-coloured homogeneous emulsion.
3. CLINICAL INFORMATION
3.1 TARGET SPECIES
Sheep (ewes) and goats (adult females).
3.2 INDICATIONS FOR USE FOR EACH TARGET SPECIES
For active immunisation of healthy ewes in flocks with recurring
mastitis problems, to reduce the
incidence of sub-clinical mastitis (reduction of udder lesions,
somatic cell count and
_S. aureus _
count)
caused by
_Staphylococcus aureus_
.
For active immunisation of healthy female goats in herds with
recurring mastitis problems, to reduce
the incidence of sub-clinical mastitis caused by
_Staphylococcus aureus _
and/or Coagulase-Negative
Staphylococci; when clinical mastitis caused by Coagulase-Negative
Staphylococci* however occurs,
the severity of clinical signs (udder and milk aspect) is reduced.
_(*Determination of the CNS species has not been performed)_
-
Onset of immunity:
Ewes: 6 weeks
Goats: has not been established (see section 4)
-
Duration of immunity: has not been established
3.3 CONTRAINDICATIONS
None.
3.4 SPECIAL WARNINGS
Vaccinate healthy animals only.
Immunisation has to be considered as one component in a complex